Duloxetine-Induced Liver Injury in Patients with Major Depressive Disorder
نویسندگان
چکیده
Duloxetine is a balanced serotonin-norepinephrine reuptake inhibitor. Duloxetine-induced liver injury in patients with preexisting liver disease or chronic alcohol use is known. However, we have found that duloxetine can also induce liver injury in cases without those risk factors. We recommend that clinicians should monitor liver function carefully following duloxetine treatment.
منابع مشابه
Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
Duloxetine is a balanced and potent serotonin and noradrenaline reuptake inhibitor (SNRI) and has adverse effects that are commonly associated with such drugs, including nausea, dry mouth, constipation, insomnia, and dizziness. Recently, duloxetine-induced liver injury has also been observed in patients with preexisting liver disease or chronic alcohol use. We investigated the effects of duloxe...
متن کاملGuideline Watch for the Practice Guideline for the Treatment of Patients With Major Depressive Disorder
Since the publication in 2000 of the APA’s Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition (1), two important safety concerns have emerged (hepatotoxicity with nefazodone and suicide risk with antidepressants), and two new antidepressants have been approved for use (escitalopram and duloxetine). This watch describes these developments as well as evid...
متن کاملDuloxetine for the management of fibromyalgia syndrome
Fibromyalgia syndrome (FMS) is a widespread pain condition associated with a wide range of additional symptoms including fatigue, insomnia, depression, anxiety and stiffness. Duloxetine is one of three medications currently FDA approved for use in FMS management. Duloxetine is a mixed serotonin and norepinephrine reuptake inhibitor (SNRI) that functions by increasing central nervous system leve...
متن کاملA randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.
This was a 12-week, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, in 354 female patients with primary fibromyalgia, with or without current major depressive disorder. Patients (90% Caucasian; mean age, 49.6 years; 26% with current major depressive disorder) received duloxetine 60 m...
متن کاملDuloxetine Induced Urinary Retention: A Case Report
Duloxetine, a dual-reuptake inhibitor of serotonin and norepinephrine, has been approved for the treatment of major depressive disorder and for stress urinary incontinence. We describe a case of a 28 years old male patient with depression with no medical, urogenital, or psychiatric illness histories. He developed severe side effect of urinary retention following 2 weeks of treatment with Duloxe...
متن کامل